Medical ethics in cosmetic injectables means treating the patient as an autonomous decision maker with sufficient information to consent meaningfully, acting in their interest by recommending only what clinical assessment supports, avoiding harm through conservative dosing and refusal protocols, and operating with fairness in pricing, access, and advertising. These principles are codified in AHPRA standards and the TGA Therapeutic Goods Advertising Code.
Why Cosmetic Injectables Need an Explicit Ethical Framework
Cosmetic injectables differ from many medical procedures because the clinical indication is patient preference rather than disease. The patient is not seeking treatment for a diagnosed condition. They are seeking a change to their appearance. This shifts the ethical considerations in specific ways.
There is no objective endpoint that defines treatment success. The endpoint is what the patient wants, mediated by what the practitioner judges is anatomically achievable and clinically safe. This makes the consultation conversation, the consent process, and the practitioner’s clinical discretion central to ethical practice in a way that does not apply equally to procedures with defined medical endpoints.
There is also a commercial dimension. Cosmetic injectable clinics charge for treatment in a market where multiple providers compete for the same patients. The commercial pressure can affect clinical decision making if it is not actively managed. An ethical framework provides the structure for managing it: the practitioner’s clinical judgement takes precedence over the commercial outcome of any individual appointment.
Patient Autonomy and Informed Consent
Autonomy is the principle that the patient is the decision maker about what happens to their body. In cosmetic injectables, autonomy depends on information. The patient cannot make an autonomous decision without understanding what is being proposed, what the alternatives are, what the risks are, and what realistic outcomes look like.
Informed consent is the practical mechanism by which autonomy is supported. It is a structured conversation, documented in the clinical record, that confirms the patient understands the planned treatment, the expected outcome, the risks at general and product specific level, the alternatives including no treatment, and the cost and review structure. Consent is renewed at each appointment because consent is specific to the planned intervention, not a one off authorisation.
The consent conversation can take longer than patients expect. This is intentional. The depth of the conversation supports the depth of the decision. Where the patient has questions, time is taken to answer them. Where the patient is uncertain, the conversation may extend across more than one appointment. The cooling off period required by AHPRA September 2025 supports this by separating consultation from treatment for new patients.
Beneficence and the Limits of What is Achievable
Beneficence is the principle that the practitioner acts in the patient’s interest. In cosmetic injectables, this includes recommending only what the consultation reveals is appropriate, declining to deliver treatment that the assessment does not support, and being clear about what an outcome will and will not deliver.
Beneficence sometimes means setting expectations rather than meeting them as expressed. A patient asking for a specific outcome may benefit from a conversation about whether the outcome is anatomically achievable, whether it would suit their facial proportions, and whether alternative approaches would deliver more of what they actually want. This conversation is uncomfortable when the patient has arrived with a clear expectation, but it is part of acting in their interest.
In practice, beneficence often produces shorter or smaller treatment than the patient initially requested. The trade off is that the result is more likely to be one the patient is satisfied with at the review appointment. Over promising and over delivering both carry significant downsides. Realistic expectation setting is the foundation of patient satisfaction across the longer term.
Non-Maleficence: First, Do No Harm
Non maleficence is the principle that the practitioner avoids causing harm. In cosmetic injectables, harm includes physical complications (vascular events, infection, asymmetry, prolonged unintended weakness), psychological harm (treatment that produces an outcome the patient is unhappy with), and harm from sequencing or layering treatments that compound problems.
Non maleficence operates through specific clinical practices. Conservative dosing reduces the probability of overcorrection. Refusal of treatment that is not clinically appropriate prevents harm before it occurs. Sequenced treatment plans avoid the situation where multiple interventions are layered before the effect of any single one is known. pretreatment screening identifies patients for whom risk is elevated and either modifies or defers treatment.
The principle is not absolute. All clinical interventions carry some risk. The practical question is whether the benefit to the patient outweighs the risk in their individual circumstances, and whether the consent conversation has supported the patient’s understanding of that trade off.
Justice in Pricing and Access
Justice in clinical practice concerns the fair distribution of benefit and burden. In cosmetic injectables, this includes how treatment is priced, who has access to it, and how the structure of the clinic affects different patient groups.
Pricing is structured around what is delivered, not around inducement. The TGA Therapeutic Goods Advertising Code prohibits price inducement based promotion of cosmetic injectables, time limited offers, and pricing structures designed to encourage immediate decisions. This protects patients from financial pressure that could compromise informed consent. Pricing is discussed at consultation and is consistent with the treatment plan agreed.
Access includes the structure of consultation. A consultation based model with cooling off periods and structured review appointments may be slower than a same day treatment model. It is also more accessible to patients who want time to consider, who are anxious about treatment, who have complex medical histories, or who are decision making across multiple visits. The structure of the clinic shapes who finds it accessible.
Refusal as an Ethical Practice
The willingness to defer or decline treatment is one of the clearest expressions of clinical ethics in cosmetic injectables. Refusal is appropriate when consultation reveals that the requested treatment is not anatomically suitable, when the patient’s expectations exceed what is realistic, when prior treatment is still settling, when the medical history makes treatment unsafe, when the patient is pregnant or breastfeeding, when the patient is under 18, or when the consultation has surfaced concerns that warrant other support before any cosmetic decision is made.
Refusal in this context is not a rejection of the patient. It is the application of clinical judgement to recommend the appropriate course of action, which sometimes is no treatment. The refusal is documented and explained, with the clinical reasoning, the conditions under which treatment may become appropriate in the future, and any relevant referrals.
A practice that does not include refusal is one in which clinical judgement is not actively shaping the treatment list. Over time, a practice that always proceeds with what the patient requests will accumulate cases that should have been declined. The discipline of refusal is part of how clinical standards are maintained.
Conflicts of Interest and the Commercial Setting
Cosmetic injectable practice is commercial. The clinic depends on patients paying for treatment. This creates a structural tension between the practitioner’s clinical interest in recommending only what is appropriate and the commercial interest in maintaining a treatment volume that supports the clinic’s operation.
The tension is managed by making the clinical judgement primary. The treatment plan is determined by what the consultation reveals, not by what the patient is willing to pay. The consultation fee is charged separately so that it is not perceived as a barrier to declining recommended treatment. Reviews are part of the standard structure rather than additional billable visits driven by the need to generate revenue.
Where a treatment is not in the patient’s clinical interest, declining it is the appropriate response even though it has a commercial cost. This is one of the structural features that makes one practitioner practice viable for conservative philosophy: there is no incentive to upsell, no commission structure on additional product, and no business model that depends on maximising treatment per visit.
Consent and the Cooling-Off Period
AHPRA September 2025 guidance for registered health practitioners performing nonsurgical cosmetic procedures introduced a mandatory cooling off period between consultation and treatment for new patients. This is an ethical mechanism that supports informed consent.
The cooling off period creates time between the consultation conversation and the moment of treatment. In that time, the patient can reflect on what was discussed, raise additional questions, consider alternatives, and decide whether to proceed without the social pressure of being already in the treatment chair. For new patients especially, this separation is important because the consultation environment can carry an implicit expectation that treatment will follow.
The practical effect is that first appointments at Core Aesthetics are consultations, not treatments. Treatment is scheduled at a subsequent appointment after the cooling off period has elapsed. This is a regulatory requirement and an ethical practice that supports patient autonomy.
Advertising Ethics and the TGA Framework
Advertising of cosmetic injectables is regulated under the TGA Therapeutic Goods Advertising Code because the products involved are classified as therapeutic goods. The framework prohibits patient endorsements about the service, before and after imagery of identifiable patients, brand name product promotion, outcome promises, superlative or emotional inducement, and price inducement or time limited pricing offers.
These restrictions are sometimes treated as marketing constraints. They are also ethical safeguards. They reduce the prevalence of misleading claims, protect patients from inducement based decision making, and limit the use of selected outcomes to imply broader probability than the data supports. Compliance is not optional. It is a condition of practising in this regulated space.
A clinic that advertises within these restrictions will look different from one that does not. The differences are visible in title language, content tone, the absence of endorsements, the absence of pricing driven calls to action. These features are not stylistic preferences. They are how regulated cosmetic injectable practice operates in Australia.
Vulnerable Patients and Body-Image Considerations
Some patients seeking cosmetic injectable treatment have body image concerns that warrant other support before any cosmetic decision is made. The consultation includes screening for indications that the underlying concern is psychological rather than aesthetic, that expectations are unrealistic in a way that suggests body dysmorphic disorder, or that the patient is making decisions under significant external pressure.
Where these indicators are present, the appropriate response is not to proceed with treatment. The consultation may include discussion of alternative support pathways, including referral to mental health services where appropriate. This is an ethical obligation that takes precedence over the patient’s stated request for treatment.
Under-18 patients are not eligible for cosmetic injectable treatment under AHPRA September 2025 guidance. This is a hard rule, not a clinical judgement. Pregnant or breastfeeding patients are also not eligible for elective cosmetic injectable treatment. These exclusions exist to protect patients during periods when the risk benefit calculation does not support elective intervention.
Continuing Professional Development as Ethical Practice
Clinical knowledge in cosmetic injectables continues to develop. New techniques, new product profiles, new safety findings, and new regulatory frameworks emerge over time. Ethical practice includes active engagement with this development through continuing professional development and ongoing review of clinical protocols.
For AHPRA registered nurses, continuing professional development is a registration requirement. The hours required are documented in the practitioner’s annual registration. Beyond the regulatory minimum, ongoing engagement with the clinical literature, peer discussion, advanced training in specific techniques, and regular review of adverse event protocols is part of operating at the standard the role requires.
For patients, this means the practitioner they see in 2026 has different knowledge than the one they would have seen in 2020, even if the practitioner is the same person. The appropriate response to evolving clinical understanding is to incorporate it into practice. This is one of the reasons consultation discussions sometimes differ from what a patient remembers from a previous appointment elsewhere.
How These Ethics Shape Daily Practice at Core Aesthetics
Core Aesthetics is operated by Corey Anderson, AHPRA registered nurse, NMW0001047575, as a one practitioner clinic. Every consultation and treatment is conducted by Corey personally. The ethical framework set out on this page is not aspirational. It is the structure within which the clinic operates daily.
First appointments are consultations only. Treatment is scheduled at a subsequent appointment after the cooling off period. Treatment recommendations follow anatomical assessment and are individualised. Dosing is conservative. Refusal is part of the practice. Reviews are scheduled as part of treatment plans rather than as optional follow ups. Documentation supports continuity, audit, and patient understanding.
The scope of practice is intentionally narrow. Cosmetic injectables only. The clinic does not offer laser treatment, skin therapy, or device based services. This focus supports the depth of clinical engagement required for the conservative, ethics led practice the clinic operates within.
Clinical accountability and how this page is reviewed
The clinical content in “Medical Ethics in Cosmetic Injectables: How Ethics Shape Daily Practice” is written and reviewed by Corey Anderson, AHPRA registered nurse (NMW0001047575). Core Aesthetics operates as a one practitioner, consultation based, low volume clinic in Oakleigh, Melbourne, which means every recommendation on this page reflects the same clinical perspective rather than a copywriter’s interpretation of it. Results vary between individuals, and any guidance written for the general reader has to acknowledge that variance, what the published evidence supports for the average patient may not be what the assessment supports for a specific patient.
Specific to medical ethics cosmetic injectables: this page describes the typical clinical picture for a healthy adult patient at the time of writing. Individual circumstances, medical history, current medications, prior cosmetic treatment, skin type, age, hormonal state, lifestyle, can shift any of the timelines and recommendations described here. The information is provided to help patients arrive at consultation already familiar with the underlying clinical reasoning, not to replace the consultation itself. Results vary between individuals; this page describes the centre of the distribution, not the edges. The clinical philosophy conservative injectables page covers an adjacent topic in more depth.
Patients reading this page who want to verify Corey Anderson’s AHPRA registration can do so directly on the AHPRA public register at ahpra.gov.au using registration number NMW0001047575. The Core Aesthetics clinic operates from 12A Atherton Road, Oakleigh VIC 3166, Tuesday to Saturday, by consultation appointment. All new patient treatment at Core Aesthetics follows a structured clinical consultation, consistent with the September 2025 AHPRA cosmetic procedures guidelines. Treatment may be scheduled for the same day as consultation or at a subsequent appointment, depending on clinical assessment and individual circumstances. Patients with questions about the content on this page can raise them at consultation; the practitioner is happy to walk through any clinical reasoning that the written content does not fully capture. Results vary between individuals, and the consultation is the appropriate place to discuss what those individual variations mean for a specific person’s treatment plan.
Is this for you?
Consider booking a consultation if
- Patients wanting to understand the ethical framework that shapes a cosmetic injectables clinic
- Patients comparing clinics and including ethical practice as part of that decision
- Patients who have experienced pressure or rushed consent elsewhere and are evaluating different clinical approaches
- Patients seeking to understand why a consultation based model differs from same day treatment models
This may not be for you if
- Anyone under 18 years of age
- Patients who are pregnant or breastfeeding
- Patients seeking same day treatment without a prior consultation appointment
- Patients seeking confirmation that a clinic will deliver any requested treatment
- Patients seeking specific clinical advice about an individual treatment decision, this requires individual consultation
Suitability is confirmed at consultation. This list is general guidance, not a substitute for clinical assessment.
Frequently asked questions
Why is the first appointment a consultation rather than treatment?
AHPRA September 2025 guidance for registered health practitioners performing nonsurgical cosmetic procedures requires a cooling off period between consultation and treatment for new patients. This separation supports informed consent by giving the patient time to reflect on the discussion before deciding to proceed. The first appointment is a structured consultation. Treatment is scheduled at a subsequent appointment.
Will the practitioner ever decline to treat me?
Yes, where the consultation reveals that the requested treatment is not clinically appropriate. Reasons may include anatomical unsuitability, expectations beyond what treatment can deliver, prior treatment still settling, medical history that makes treatment unsafe, pregnancy or breastfeeding, age under 18, or other consultation findings. Refusal is documented and explained, with the clinical reasoning and any alternative options. This is part of the practice, not a failure of consultation.
How does the clinic handle patients with body image concerns?
Consultation includes screening for indicators that the underlying concern is psychological rather than aesthetic, that expectations are unrealistic in a way that warrants further assessment, or that the patient is making decisions under external pressure. Where these indicators are present, the appropriate response is to not proceed with treatment and to discuss alternative support pathways, including referral where appropriate.
Why doesn’t the clinic offer price inducements or time limited pricing?
The TGA Therapeutic Goods Advertising Code prohibits price inducement based promotion, time limited offers, and pricing structures designed to encourage immediate decisions for cosmetic injectables. These restrictions exist to protect patients from financial pressure that could compromise informed consent. Pricing is discussed at consultation and is consistent across patients with the same treatment plan.
Is the consultation fee separate from treatment cost?
The consultation fee is charged separately so that the cost of consultation does not function as a barrier to declining recommended treatment. The patient may attend the consultation, receive the assessment and treatment plan, and decide not to proceed. The consultation has clinical value in its own right, including the documented assessment, the treatment plan, and the discussion of suitability and alternatives.
What happens if I disagree with the treatment recommendation?
The consultation includes discussion of alternatives, including the alternative of no treatment. Where a patient disagrees with the recommendation, the practitioner explains the clinical reasoning, the basis for the recommendation, and what the alternative options would involve. The patient may decline the recommendation or seek a second opinion from another practitioner. The practitioner does not deliver treatment that is not clinically indicated regardless of patient preference.
How do I know the practitioner is current on clinical standards?
AHPRA registration requires documented continuing professional development annually. The practitioner’s registration status can be verified directly via the AHPRA public register using the registration number NMW0001047575. Beyond the regulatory minimum, ongoing engagement with clinical literature, peer discussion, and protocol review is part of operating at the standard required by the role.
Who writes and reviews the clinical content on this page?
The clinical content is written and reviewed by Corey Anderson, an AHPRA registered nurse (NMW0001047575) and the practitioner at Core Aesthetics in Oakleigh, Melbourne. Core Aesthetics operates as a one practitioner, consultation based, low volume clinic, which means the recommendations on this page reflect the same clinical perspective patients encounter at the consultation itself. Results vary between individuals, and personalised guidance is provided at consultation.